Director, Immunometabolic Gut-Brain Immunology

Lilly; Boston (MA); On-site; USD 168,000 - 290,000; Full time

Benefits offered by this job

Company bonus

401(k) plan

Comprehensive benefits

Job summary

Lilly is seeking a Senior Scientific Leader to explore gut–brain axis hormones at the intersection of metabolism, neurobiology, and immunology. You will shape strategy, lead a matrixed team, and guide collaborations to advance immunometabolic health.

The role emphasizes hands‑on leadership, strategic framing of central questions, data interpretation across in vitro and in vivo systems, and translating insights into portfolio‑relevant directions. A strong publication/patent record is expected.

Qualifications

• Ph.D. and relevant post‑doctoral training in immunology, neuroscience, immunometabolism, or related field.
• 8+ years of relevant experience in pharmaceutical and/or biotechnology companies.
• Experience in gut‑brain axis hormones and peptides biology and immunology, evidenced by peer‑reviewed manuscripts and/or patents.

Responsibilities

• Develop scientific strategy linking gut–brain axis hormones to metabolism, neurobiology, and immunology.
• Build and lead a matrixed, multi‑disciplinary team to execute the strategy.
• Manage external collaborations to support the scientific strategy and ensure alignment with portfolio needs.

Skills

Leadership

Cross-functional collaboration

Communication

Attention to detail

Organizational skills

Team culture

AI in business

Due diligence

Drug discovery

Education

Ph.D. in immunology, neuroscience, immunometabolism, or related field

Job description

Lilly is seeking a Senior Scientific Leader to explore gut–brain axis hormones at the intersection of metabolism, neurobiology, and immunology. You will shape strategy, lead a matrixed team, and guide collaborations to advance immunometabolic health.

The role emphasizes hands‑on leadership, strategic framing of central questions, data interpretation across in vitro and in vivo systems, and translating insights into portfolio‑relevant directions. A strong publication/patent record is expected.